Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: An Open-label Cohort Study in Real Clinical Practice
Status: Recruiting
Location: See location...
Intervention Type: Combination product
Study Type: Observational
SUMMARY
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 80
Healthy Volunteers: f
View:
• Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS
• The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital
• Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital
• Patients with complete clinical data followed up for at least 1 year
Locations
Other Locations
China
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College
RECRUITING
Nanjing
Contact Information
Primary
Youjun ZHENG
19943909917@163.com
1+86 9943909917
Time Frame
Start Date: 2020-01-01
Estimated Completion Date: 2025-06-21
Participants
Target number of participants: 100
Treatments
Moderate to severe hidradenitis suppurativa
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College